ESO-1:157-165(165V) Peptide
A 9-residued peptide vaccine consisting of amino acids 157 through 165 of the cancer/testis (CT) antigen ESO-1. Modified at position 165 (cysteine to valine) to improve immunogenicity, ESO-1:157-165(165v) peptide administered as a vaccine may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for ESO-1, resulting in decreased tumor growth. ESO-1 is expressed in a variety of cancers, including melanoma, breast, bladder, prostate, and hepatocellular cancers. (NCI04)
Exact Synonyms
ESO-1:157-165(165V) Peptide
class Information
code
C2754
Has_Target
Legacy Concept Name
ESO-1_157-165_165v_Peptide
NSC Number
717388
Preferred_Name
ESO-1:157-165(165V) Peptide
Semantic_Type
- Amino Acid, Peptide, or Protein
- Pharmacologic Substance
UMLS_CUI
C1512136
class Relations
Subclass of
- Antineoplastic Vaccine
- Peptide Vaccine
- Chemical_Or_Drug_Has_Mechanism_Of_ActionsomeAntigen Sensitization
- Chemical_Or_Drug_Has_Physiologic_EffectsomeT-Cell Activation
- Chemical_Or_Drug_Has_Physiologic_EffectsomeInhibition of Cell Proliferation
- Chemical_Or_Drug_Has_Physiologic_EffectsomeImmunopotentiation
- Chemical_Or_Drug_Affects_Cell_Type_Or_TissuesomeCytotoxic T-Lymphocyte